Although these results suggest that IGF-II receptor may differentially regulate various lysosomal enzymes, increased levels of mature cathepsins B and D as well as β-glucuronidase, apart from degradation of cellular proteins, can influence AD pathology via other pathways including APP/Aβ metabolism. Here, IGF2R is linked to Alzheimer disease.